2005, ISBN: 9783790816679

Taschenbuch

[ED: Taschenbuch], [PU: Physica], The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topp… Mehr…

[ED: Taschenbuch], [PU: Physica], The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US 33 billion in 2003 compared to around US 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year., DE, [SC: 0.00], Neuware, gewerbliches Angebot, 296, [GW: 476g], Banküberweisung, PayPal, Sofortüberweisung<

2005, ISBN: 9783790816679

Taschenbuch

[ED: Taschenbuch], [PU: Physica], The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topp… Mehr…

[ED: Taschenbuch], [PU: Physica], The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US 33 billion in 2003 compared to around US 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year., DE, [SC: 0.00], Neuware, gewerbliches Angebot, 296, [GW: 476g], Banküberweisung, PayPal, Sofortüberweisung<

2005, ISBN: 9783790816679

Taschenbuch

[ED: Taschenbuch], [PU: Physica Verlag], Neuware - The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European compa… Mehr…

[ED: Taschenbuch], [PU: Physica Verlag], Neuware - The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US 33 billion in 2003 compared to around US 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year., DE, [SC: 0.00], Neuware, gewerbliches Angebot, 235x155x16 mm, 296, [GW: 476g], Banküberweisung, PayPal<

2003, ISBN: 9783790816679

The productivity in pharmaceutical research and development faces intense pres­ sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared t… Mehr…

The productivity in pharmaceutical research and development faces intense pres­ sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re­ cord level of close to US$ 1 billion today. As a result, any failure of a new sub­ stance in the R&D process can lead to considerable losses, and the risks of introduc­ ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year., Physica<

2005, ISBN: 3790816671

2006 Kartoniert / Broschiert Pharmaindustrie, Wirtschaftswissenschaft, Management: Innovation, CollaborationManagement; InnovationandTechnologyManagement; pharmaceuticalindustry; riskma… Mehr…

2006 Kartoniert / Broschiert Pharmaindustrie, Wirtschaftswissenschaft, Management: Innovation, CollaborationManagement; InnovationandTechnologyManagement; pharmaceuticalindustry; riskmanagement; innovation, with dust cover 11, [PU:Physica-Verlag HD; Physica]<